Tirzepatide vs Retatrutide
Medically reviewed by the Rite Aid Health Team · Last updated August 14, 2026
Tirzepatide is an approved weekly dual agonist available by prescription. Retatrutide is a weekly triple agonist in late-stage development. Its phase 3 TRIUMPH-1 study is completed, but the ClinicalTrials.gov record does not yet post results. That makes this a comparison between established treatment and an investigational option awaiting a fuller phase 3 record.
Talk to a clinician about treatment options
GLP-1 medicines are prescription treatments. A licensed provider can review medical history and help select and manage an appropriate option. Peptides for weight loss provides the broader context.
At a glance
| Comparison | Tirzepatide | Retatrutide |
|---|---|---|
| Common goal | Approved weight management and type 2 diabetes products | Obesity, diabetes, and related conditions in clinical trials |
| Mechanism | GIP and GLP-1 receptor agonist | GIP, GLP-1, and glucagon receptor agonist |
| Evidence | Completed phase 3 programs, outcomes research, and approved labels | Published phase 2 results; phase 3 program underway with TRIUMPH-1 completed and results not posted |
| Route and timing | Weekly subcutaneous injection | Weekly subcutaneous injection in trials |
| Dosage | Zepbound starts at 2.5 mg weekly and titrates to labeled maintenance doses. Zepbound label | Trial doses and titration schedules only; no approved patient dosage |
| Side effects | Mostly gastrointestinal, with product-specific serious warnings | Mostly gastrointestinal in phase 2; phase 3 will define the profile more fully |
| Monitoring | Label-based clinical monitoring | Protocol-based research monitoring |
| Access and status | FDA approved by prescription | Investigational; access through eligible clinical trials |
What the third receptor may change
Retatrutide adds glucagon-receptor activity to the two receptors targeted by tirzepatide. Researchers are testing whether that combination increases energy expenditure and weight loss while preserving an acceptable safety profile. Phase 2 results support continued study, not an approved comparison claim.
Which option can be considered today
Tirzepatide is the clinical option because its finished products, indications, dosage schedules, manufacturing, and safety information have FDA review. Retatrutide remains a research option for eligible trial participants.
Why the compounds are not combined
Retatrutide already includes GIP and GLP-1 activity, so adding tirzepatide would duplicate two receptor targets. No approved or trial-backed regimen combines them.
Related
Sources
Educational information only. Any GLP-1 treatment should be started and supervised by a licensed clinician.
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
No. It remains investigational and is available only through eligible clinical trials.
TRIUMPH-1 is completed, but its ClinicalTrials.gov record does not yet post results. Other phase 3 studies continue.